A novel
strategy for lead identification that we have dubbed the
“Pocket-to-Lead” strategy is demonstrated using HIV-1
protease as a model target. Sometimes, it is difficult to obtain hit
compounds because of the difficulties in satisfying the complex pharmacophoric
features. In this study, a virtual fragment hit which does not match
all of the pharmacophore features but has key interactions and vectors
that could grow into remaining pharmacophore features was optimized in silico. The designed compound 9 demonstrated
weak but evident inhibitory activity (IC50 = 54 μM),
and the design concept was proven by the co-crystal structure. Then,
structure-based drug design promptly gave compound 14 (IC50 = 0.0071 μM, EC50 = 0.86 μM),
an almost 10,000-fold improvement in activity from 9.
The structure of the designed molecules proved to be novel with high
synthetic feasibility, indicating the usefulness of this strategy
to tackle tough targets with complex pharmacophore.